期刊文献+

湖北地区非小细胞肺癌EGFR基因突变及其意义的研究 被引量:10

Detection of Epidermal Growth Factor Receptor(EGFR)Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC) of Hubei Province
下载PDF
导出
摘要 目的探讨湖北地区非小细胞肺癌(NSCLC)患者中 EGFR基因的突变情况,评价湖北地区 EGFR突变的检测力度,为临床合理选择酪氨酸激酶抑制剂提供可靠的实验依据。方法采用 PCR-sanger测序法以及 ADx-ARMS法检测2010~2015年期间253例肺癌标本中 EGFR基因突变情况,探讨不同检测手段的敏感度,探讨不同性别、不同组织分型间EGFR不同外显子的突变频率差异及其临床意义。结果253例肺癌标本中共检测到突变位点93个,以 E19和 E21的突变最为常见,占比为53.76%和35.38%。ADx-ARMS法的 EGFR总突变检出率明显高于 Sanger测序法(P=0.001)。女性肺癌患者的检出率明显高于男性(P=0.001)。不同组织分型中,腺癌(38.01%)的检出率最高,腺鳞癌(30.77%)与大细胞癌(20%)次之,鳞癌(4.55%)较低。无吸烟史的肺癌患者检出率(51.6%,81/157)明显高于有吸烟史患者(24%,12/50)。结论与PCR-sanger测序法相比,ADx-ARMS法对临床筛选 EGFR-TKI治疗的受益亚群,预测 EGFR-TKI疗效更为敏感有意义。湖北地区女性肺癌患者中 EGFR突变频率明显高于男性,与激素水平变化及吸烟状况有关。 Objective To evaluated the prevalence of EGFR mutations in Hubei region,to provide reliable experimental basis for reasonable screening TKI beneficiaries in clinic.Methods EGFR mutation of 253 patients diagnosed with NSCLC in Hu-bei region during 2010 to 2015 was detected by PCR-sanger sequencing and ARMS assay,to investigate the sensitivity of dif-ferent methods,to explore the frequency and clinical significance of EGFR mutation in different gender,in different histologi-cal type and different exons.Results 93 of 253 NSCLC patients harbored EGFR mutation,mainly occurred in exon 19 and 21,accounting for 53.76% and 35.38% of the total EGFR mutation rate,respectively.ADx-ARMS method showed higher sensitivity (P=0.001).The mutation detection rate of female NSCLC was significantly higher than that of male NSCLC (P=0.001).The observed incidence of EGFR mutations in patients with adenocarcinomas (38.01%)was the highest in differ-ent histological type,followed by glandular squamous cell carcinoma (30.77%),large cell carcinoma (20%)and squamous cell carcinoma (4.55%).Nonsmoking patients had a higher EGFR mutation frequency (51.6%,81/157)than those with a history of smoking (24%,12/50).Conclusion ARMS assay was more sensitive and more convenient detection method for clinical screening for EGFR-TKI treatment subpopulation.The mutation rate of female NSCLC was significantly higher than that of male NSCLC in Hubei Province.Speculated that the sexual differences in NSCLC with EGFR mutation frequencies were related to hormone levels and smoking status.
出处 《现代检验医学杂志》 CAS 2016年第3期7-11,15,共6页 Journal of Modern Laboratory Medicine
基金 国家自然基金项目(81200389,8110059) 武汉大学青年教师自主科研项目(2042015Kf0113)
关键词 非小细胞肺癌 EGFR突变 PCR-sanger测序 ARMS扩增 NSCLC EGFR mutation PCR-sanger sequencing ARMS
  • 相关文献

参考文献6

二级参考文献58

  • 1鲍云华,李俭杰.介绍新的实体瘤治疗反应评价标准(RECIST)[J].中国肺癌杂志,2005,8(1):77-78. 被引量:110
  • 2宋萍,李坚,殷凯生.检测外周血表皮生长因子受体表达在诊断肺癌微转移中的临床意义[J].江苏大学学报(医学版),2005,15(5):398-400. 被引量:5
  • 3Franklin WA. Veve R, Hirsch FR, et al. Epidermal growth factor receptor family in lung cancer and pre?malignancy[J]. Semin Oncol, 2002,29 (1 suppl 4): 3- 14.
  • 4Cohen S. Purification of the receptor for epidermal growth factor from A-431 cells: its function as a ty?rosyl kinase[J]. Methods Enzymol, 1983 (99): 379- 387.
  • 5Kosaka T, Yatabe Y , Endoh H. et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications[J]. Cancer Res, 2004,64(24):8919-8923.
  • 6Lynch T],Bell DW,Sordella R,et al. Activating mu?tations in the epidermal growth factor receptor under?lying responsiveness of non-small-cell lung cancer to gefitinib[J]. N EnglJ Med,2004. 350(21): 2129- 2139.
  • 7Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as de?terminants of epidermal growth factor receptor tyro?sine kinase inhibitors sensitivity in lung cancer[J]. Cancer Sci, 2007,98(12) : 1817-1824.
  • 8Toyooka S, Yatabe Y. Tokumo Mver al. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung[J]. Int] Cane- er,2006,118(6):1588-1590.
  • 9Tatematsu A. Shimizu], Murakami Y, et al. Epider?mal growth factor receptor mutations in small cell lung cancer[J]. Clin Cancer Res, 2008,14(19): 6092- 6096.
  • 10Mok T, Wu YL, Thongprassert S, et al. Phase III. randomized, open-label, first-line study of gefitinib vs catboplatiri/ paclitaxel in clinically selected patients with advanced non-small cell lung cancer (ESMO 2008,LBA2)[J]. Ann Oncol,2008,19(suppI8): VJH.

共引文献48

同被引文献75

引证文献10

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部